Custom T cells for blood cancers with specific mutations
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a blood cancer like AML, MDS, CML, CMML, T-ALL, or multiple myeloma
- Your cancer must have a specific TP53 or RAS mutation (e.g., TP53 R175H or Ras G12D) and a certain HLA type (a protein marker on your cells)
- You must be between 18 and 75 years old
- You should be in good enough health to undergo intensive care if needed
- If you've had a stem cell transplant, it must be from a fully matched donor and at least 100 days ago
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
This trial tests a personalized cell therapy where your own immune cells are collected, modified to better attack cancer, and then returned to you. It is for people with various solid tumors and lymphomas whose cancer cells have specific markers.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
This early-phase study tests a personalized treatment made from your own immune cells to attack solid tumors that have not responded to standard care. If you qualify, the team will collect blood cells, prepare the therapy, and give it back to you with close monitoring for safety and early signs of benefit.
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
Hear when a new Blood Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.